ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO377

Type IV Collagen Variants in Patients With Polycystic Kidneys

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic


  • Lanktree, Matthew B., McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
  • Haghighi, Amirreza, University Health Network, Toronto, Ontario, Canada
  • Khowaja, Saima, University Health Network, Toronto, Ontario, Canada
  • Iliuta, Ioan-Andrei, University Health Network, Toronto, Ontario, Canada
  • Paterson, Andrew, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Pei, York P., University Health Network, Toronto, Ontario, Canada

Gene panel and whole exome sequencing of patients with cystic kidney disease have led to the discovery of unexpected phenotypic heterogeneity of genetic kidney diseases. Mutations in type IV collagen genes (COL4A3/COL4A4/COL4A5) have long been recognized as the cause of Alport syndrome and thin basement membrane disease. More recently, type IV collagen mutations have also been associated with focal segmental glomerulosclerosis. Among patients clinically selected and submitted for genetic assessment of polycystic kidneys, we sought to compare the prevalence of type IV collagen mutations between those with and without a pathogenic PKD1 or PKD2 variant.


808 participants of the Ontario Polycystic Kidney Disease registry provided DNA samples for targeted gene panel sequencing. Sequencing results from PKD1, PKD2, COL4A3, COL4A4, and COL4A5 were analyzed here. Participant charts were reviewed to analyze their cystic phenotype and obtain measurements of total kidney volume and kidney function.


34 participants had a suspected pathogenic rare variant in a type IV collagen gene with a median age of 49 (range 24 – 72). One male was hemizygous for a COL4A5 variant (p.P1517T), while the remaining variants were carriers of a heterozygous variant. Type IV collagen variants were more prevalent in patients who did not also have a PKD1 or PKD2 rare variant compared to those with them (31 out of 315 patients compared to 3 out of 493; P < 1 x 10-5). Of 31 type IV collagen variants without a PKD1 or PKD2 mutation 20 had atypical cystic distributions, 11 had a cystic appearance consistent with typical autosomal dominant polycystic kidney disease (ADPKD), and only 2 had a high-risk Mayo classification (class C or worse). 3 of 34 patients with a type IV collagen variant had reached an eGFR < 30 ml/min/1.73m2.


In patients with polycystic kidneys and gene panel sequencing results, type IV collagen mutations were more common in those without a PKD1 or PKD2 mutation compared to those with them, suggesting type IV collagen mutations may be associated with a cystic phenotype. Both typical and atypical cystic imaging patterns were observed but generally smaller age- and height-adjusted kidney volumes were observed.


  • Private Foundation Support